Infectious Disease Control
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients
BEIJING, Dec. 14, 2022 /PRNewswire/ -- To echo China's new guidelines for COVID-19 prevention and control, local governments and hospitals across the country have been optimizing medical services and the allocation of medical resources to face a likely surge in patients and take better care of th...
Fosun International Receives "ESG Leading Enterprise Award" and "ESG Leading Social Initiative Award" from Bloomberg Businessweek/Chinese Edition
HONG KONG, Dec. 14, 2022 /PRNewswire/ -- On 12 December 2022, the results of the fourth ESG Leading Enterprise Awards 2022, which was organized by the Chinese Edition of Bloomberg Businessweek in partnership with Deloitte, one of the world's largest accounting firms, and with the support from Inv...
CGTN: The Chinese are sharing their COVID experiences as policy optimized
BEIJING, Dec. 13, 2022 /PRNewswire/ -- Vincent Zhong is a Chinese digital gadget YouTuber with more than 372,000 followers. Aside from smartphones, earbuds and laptops, Zhong recently unboxed a special object: COVID-19. "I'm screwed," Zhong said in a video showing a positive COVID test result on ...
CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation
BEIJING, Dec. 12, 2022 /PRNewswire/ -- Under the Belt and Road Initiative (BRI),
China-Arab cooperation in the fields of infrastructure, space and health has
been continuously developed in a sustainable manner.
China further optimizes COVID-19 response with new measures
BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from People's Daily: Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by the country on further optimizing the COVID-19 response, so as to contain the epidemi...
China recalibrates its COVID-19 response strategy
BEIJING, Dec. 12, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn onDecember 7 that they would no longer be required to take the ...
Asia embraces the dawn
HONG KONG, Dec. 10, 2022 /PRNewswire/ -- A photo exhibition that captures the changes in Asian people's daily lives under the COVID-19 pandemic and encourages people to move forward opened inHong Kong on Friday. Co-organized by China Daily and the Asia News Network, the Changing Asia – New Norma...
Australian Scientists Honoured with the Grand Hamdan Award
DUBAI, UAE, Nov. 25, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future. The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of SheikhRas...
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease ar...
Manulife Hong Kong expands partnership with Christian Family Service Centre to support long COVID recovery in underserved communities
New program to provide comprehensive healthcare services to empower sustained health and better wellbeing HONG KONG, Nov. 17, 2022 /PRNewswire/ -- Manulife Hong Kong today announced the launch of "Manulife Health Voucher Program – COVID Recovery" (hereafter referred to as the "Program") in partn...
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021
VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...
Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022
XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipmen...
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
* The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary * Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains * The trial showed no benefit for a bivalent vaccin...
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...
GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis
SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supportedChulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production a...
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults
GAITHERSBURG, Md., Oct. 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received eme...
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...
The Grand Hamdan Award goes to two scientists in Australia
DUBAI, UAE, Oct. 19, 2022 /PRNewswire/ -- According to an official announcement
made recently inDubai, Prof. Ian Hector Frazer and the Late Dr. Jian Zhou are
the winners of the Grand Hamdan Award for the topic of – Infectious Diseases in
the Award's 12th term (2021-2022).
Week's Top Stories
Most Reposted
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
[Picked up by 298 media titles]
2024-12-31 14:18Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 281 media titles]
2024-12-30 15:33Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
[Picked up by 276 media titles]
2025-01-03 19:33Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
[Picked up by 276 media titles]
2025-01-02 08:16CKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
[Picked up by 258 media titles]
2024-12-31 22:30